{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:06:03Z","timestamp":1792242363996,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018439","name":"SK Life Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018439","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024207","name":"Angelini Pharma Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.yebeh.2026.110960","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:09:34Z","timestamp":1773137374000},"page":"110960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Seizure-free days as a clinical outcome measure of reduced epilepsy burden: 5-year outcomes with cenobamate treatment"],"prefix":"10.1016","volume":"179","author":[{"given":"Jos\u00e9 M.","family":"Serratosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gil-Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-1640","authenticated-orcid":false,"given":"Christian","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthinathan","family":"Thangavelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1288-5743","authenticated-orcid":false,"given":"Elena","family":"Alvarez-Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2026.110960_b0005","doi-asserted-by":"crossref","DOI":"10.1111\/ane.13257","article-title":"Seizure freedom as an outcome in epilepsy treatment clinical trials","author":"Halford","year":"2020","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"10.1016\/j.yebeh.2026.110960_b0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1528-1157.2002.32201.x","article-title":"Seizure reduction and quality of life improvements in people with epilepsy","volume":"43","author":"Birbeck","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110960_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107796","article-title":"Cenobamate treatment of focal-onset seizures: quality of life and outcome during up to eight years of treatment","volume":"116","author":"Elizebath","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2026.110960_b0020","unstructured":"Leidy NK, Elixhauser A, Vickrey B, Means E, Willian MK. Seizure frequency and the health-related quality of life of adults with epilepsy. 1999. Neurology 2001;57(11 suppl 4):S69-S73."},{"issue":"5","key":"10.1016\/j.yebeh.2026.110960_b0025","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s40120-023-00510-8","article-title":"Determining the relationship between seizure-free days and other predictors of quality of life in patients with Dravet syndrome and their carers from FFA registration studies","volume":"12","author":"Pinsent","year":"2023","journal-title":"Neurol Ther"},{"issue":"7","key":"10.1016\/j.yebeh.2026.110960_b0030","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/epi.17618","article-title":"Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: post hoc analysis of patients receiving cannabidiol in two randomized controlled trials","volume":"64","author":"Auvin","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110960_b0035","unstructured":"Ontozry [summary of product characteristics]. Rome, Italy: Angelini Pharma S.p.A.; June 28, 2023."},{"key":"10.1016\/j.yebeh.2026.110960_b0040","unstructured":"XCOPRI\u00ae (cenobamate tablets), for oral use, CV [prescribing information]. Paramus, NJ: SK Life Science, Inc.; August, 2025."},{"issue":"11","key":"10.1016\/j.yebeh.2026.110960_b0045","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/epi.16718","article-title":"Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action?","volume":"61","author":"Guignet","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110960_b0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2026.110960_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173117","article-title":"Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate","volume":"879","author":"Sharma","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"22","key":"10.1016\/j.yebeh.2026.110960_b0060","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yebeh.2026.110960_b0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2026.110960_b0070","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.yebeh.2026.110960_b0075","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","article-title":"Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"99","author":"Klein","year":"2022","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.yebeh.2026.110960_b0080","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/epi.17007","article-title":"Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study","volume":"62","author":"French","year":"2021","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2026.110960_b0085","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1528-1167.2011.03354.x","article-title":"Do antiepileptic drugs or generalized tonic-clonic seizure frequency increase SUDEP risk?","volume":"53","author":"Hesdorffer","year":"2012","journal-title":"A combined analysis Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2026.110960_b0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s42466-023-00265-5","article-title":"Determinants of quality of life in adults with epilepsy: a multicenter, cross-sectional study from Germany","volume":"5","author":"Siebenbrodt","year":"2023","journal-title":"Neurol Res Pract"},{"key":"10.1016\/j.yebeh.2026.110960_b0095","first-page":"1","article-title":"Seizure burden and healthcare resource utilization among people living with drug-resistant focal epilepsy in the United States","author":"Mao","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.yebeh.2026.110960_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108239","article-title":"The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome","volume":"123","author":"Auvin","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2026.110960_b0105","doi-asserted-by":"crossref","DOI":"10.1111\/dmcn.15187","article-title":"Caregiver assessment of quality of life in individuals with genetic developmental and epileptic encephalopathies","author":"Cohen","year":"2022","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2026.110960_b0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ane.13659","article-title":"Onset of efficacy and adverse events during cenobamate titration period","volume":"146","author":"Steinhoff","year":"2022","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.yebeh.2026.110960_b0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2468-1253(21)00467-2","article-title":"Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations","volume":"7","author":"Klein","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.yebeh.2026.110960_b0120","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.seizure.2007.01.004","article-title":"Comparative retention rates and long-term tolerability of new antiepileptic drugs","volume":"16","author":"Chung","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2026.110960_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106940","article-title":"Efficacy of cenobamate by focal seizure subtypes: post-hoc analysis of a phase 3, multicenter, open-label study","volume":"183","author":"Rosenfeld","year":"2022","journal-title":"Epilepsy Res"},{"issue":"12","key":"10.1016\/j.yebeh.2026.110960_b0130","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1111\/epi.17091","article-title":"Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study","volume":"62","author":"Sperling","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110960_b0135","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","article-title":"Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations","volume":"11","author":"Smith","year":"2022","journal-title":"Neurol Ther"},{"issue":"1","key":"10.1016\/j.yebeh.2026.110960_b0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/epi.17134","article-title":"Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program","volume":"63","author":"Sander","year":"2022","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2026.110960_b0145","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/epi.16573","article-title":"Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: analysis of four open-label extension studies","volume":"61","author":"Rektor","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110960_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106705","article-title":"Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: a long-term, open-label extension of a randomized, controlled trial","volume":"176","author":"Inoue","year":"2021","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.yebeh.2026.110960_b0155","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/epi.17496","article-title":"Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: four-year results from the expanded access program","volume":"64","author":"Szaflarski","year":"2023","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2026.110960_b0160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","article-title":"Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis","volume":"82","author":"Lattanzi","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2026.110960_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109653","article-title":"Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: a systematic review and network meta-analysis","volume":"152","author":"Tong","year":"2024","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.yebeh.2026.110960_b0170","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/epi.17564","article-title":"Failure to use new breakthrough treatments for epilepsy","volume":"64","author":"Klein","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110960_b0175","first-page":"1","article-title":"Cenobamate for the treatment of focal epilepsies","author":"Strzelczyk","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.yebeh.2026.110960_b0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1474-4422(19)30434-X","article-title":"Cenobamate: new hope for treatment-resistant epilepsy","volume":"19","author":"Arnold","year":"2020","journal-title":"Lancet Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:46:17Z","timestamp":1777617977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505026000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"alternative-id":["S1525505026000818"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.110960","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seizure-free days as a clinical outcome measure of reduced epilepsy burden: 5-year outcomes with cenobamate treatment","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.110960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110960"}}